Core Viewpoint - The company, Zhongmu Industrial Co., Ltd., held its 13th temporary board meeting of the 9th session on November 13, 2025, where several key resolutions were passed, including the revision of the audit committee's rules and the decision to waive the right of first refusal for a subsidiary's equity [1][2][5]. Group 1: Board Meeting Resolutions - The board unanimously approved the revision of the "Rules of Procedure for the Audit Committee of Zhongmu Industrial Co., Ltd." with a vote of 7 in favor, 0 against, and 0 abstentions [2][3]. - The revised rules were disclosed on the Shanghai Stock Exchange website on the same day [4]. - The board also agreed to waive the right of first refusal for 4.04% equity in Zhongpu Biopharmaceutical Co., Ltd., valued at approximately 17.514 million yuan, to optimize business layout [5][10]. Group 2: Upcoming Shareholder Meeting - The company will hold its 2025 third temporary shareholder meeting on December 1, 2025, with a vote conducted both in-person and online [6][7]. - The meeting will take place at the company's headquarters in Beijing, starting at 1:30 PM [28][29]. - All resolutions discussed in the board meeting will be presented to the shareholders for approval [31].

Core Insights - The Inner Mongolia Autonomous Region's technology transaction post-subsidy program has allocated 68.92 million yuan to support 856 technology transfer projects, enhancing the conversion of scientific achievements into practical applications [1] - The program aims to provide incentives for technology transfer and related services, targeting three main entities: technology demanders, suppliers, and transfer service institutions [1] - The funding is designed to stimulate technological upgrades in local enterprises, fostering high-quality economic development in the region [1] Group 1: Company Initiatives - Inner Mongolia Jinyu Baoling Biological Pharmaceutical Co., Ltd. has received 1.436 million yuan in post-subsidy funding, which will be directed towards ongoing R&D projects and capacity expansion [2] - The company is collaborating with Guangdong Lanyu Biotechnology Co., Ltd. and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. to develop advanced vaccines, enhancing its technological capabilities and market competitiveness [2] - The funding is expected to support the health of the livestock breeding industry by ensuring the effective application of new technologies [2] Group 2: Industry Impact - The post-subsidy program has been tailored to meet the diverse innovation needs across various sectors, including pharmaceuticals, rare earths, and financial services [3][4] - In the pharmaceutical sector, companies like Lianbang Pharmaceutical (Inner Mongolia) Co., Ltd. are using the subsidies for process upgrades and green technology adoption, aiming to improve product quality and sustainability [3] - The rare earth industry is also benefiting, with companies like China Northern Rare Earth Group investing in new materials and technologies to enhance product value [3] Group 3: Policy Effectiveness - The policy is designed to ensure that subsidies are allocated to key innovation areas, such as green processes and digital transformation in service industries [4] - The program facilitates a seamless integration of academic research and industrial needs, exemplified by Inner Mongolia Mengniu Dairy Group's project that combines university resources with market demands [6] - The funding not only reduces innovation risks for companies but also promotes a virtuous cycle of research output, industrial application, and market feedback [7]

Core Insights - The biopharmaceutical industry in Hohhot is experiencing rapid growth, driven by private enterprises and strategic initiatives focused on technological innovation and industrial chain enhancement [1][6] - Hohhot aims to establish itself as a leading hub for green biopharmaceuticals in Northern China, leveraging its industrial advantages to accelerate the transformation and commercialization of new technologies [6] Group 1: Industry Development - Hohhot is cultivating six major industrial clusters with a focus on biopharmaceuticals, achieving significant milestones such as the successful implementation of the world's first mRNA vaccine and intelligent manufacturing projects [1] - The city has over 60 biopharmaceutical companies, 143 innovation platforms, and 117 research institutions, with a projected industry output value of 20.25 billion yuan in 2024, accounting for approximately 7.9% of the city's industrial output [3] Group 2: Technological Innovation - Companies like Jinyu Biotechnology have pioneered technologies in large-scale cell culture and vaccine quality standards, contributing to advancements in vaccine development and production [1][4] - Innovative packaging technologies for fermentation agents and the development of vaccines such as the Brucella vaccine highlight the ongoing technological breakthroughs within the industry [2] Group 3: Collaborative Ecosystem - Hohhot has established a multi-level collaborative innovation ecosystem involving government, industry, academia, and research institutions, focusing on key technologies in animal vaccine production [4] - Partnerships between enterprises and academic institutions have led to significant advancements, such as the establishment of the largest lactic acid bacteria resource bank and successful technology transfers [4] Group 4: Policy Support - The local government has introduced various policies to support high-quality development in the biopharmaceutical sector, including financial incentives totaling 14 million yuan for innovation platforms and vaccine projects [5]